Praluent HSA/FSA Eligibility and Submission: Complete 2026 Guide

Is Praluent HSA and FSA Eligible?

Praluent (alirocumab) is eligible for payment or reimbursement through both a Health Savings Account (HSA) and a Flexible Spending Account (FSA). The legal basis is IRS Publication 502, which classifies prescription drugs as qualified medical expenses. Because alirocumab requires a valid prescription from a licensed prescriber, it meets the definition automatically.

The IRS Rule That Governs This

IRS Publication 502 states: "You can include in medical expenses amounts you pay for prescribed medicines or drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." Praluent clears that threshold on both counts.

The FDA granted Praluent original approval on July 24, 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. A 2021 label update confirmed its cardiovascular risk-reduction indication. Both indications carry prescription status, so HSA/FSA eligibility applies regardless of which diagnosis drives your prescription. The full prescribing information is available at the FDA.

HSA vs. FSA: Key Practical Differences

HSA funds roll over indefinitely; there is no deadline to spend. FSA funds are subject to the "use-or-lose" rule, meaning unspent balances generally forfeit at plan year end (some employers offer a grace period or up to a $640 carryover in 2026). If you have both account types, spending FSA dollars first is usually the better move because HSA balances keep growing tax-free.

To contribute to an HSA, you must be enrolled in a qualifying High-Deductible Health Plan (HDHP). The 2026 IRS contribution limits are $4,300 for self-only coverage and $8,550 for family coverage. Praluent's cost per injection cycle sits well within those limits for most patients who would benefit from using pre-tax dollars.

How to Pay for Praluent With HSA or FSA Funds

There are two pathways: pay directly at point-of-sale using your HSA/FSA debit card, or pay out-of-pocket first and submit for reimbursement later.

Option 1: Pay at the Pharmacy Counter

Most major pharmacy chains (CVS, Walgreens, Walmart, specialty pharmacies such as CVS Specialty or Accredo) accept HSA and FSA debit cards directly. Hand the pharmacist your HSA/FSA card at pickup. The transaction processes like a standard debit purchase. Keep the itemized pharmacy receipt; your plan administrator or the IRS may ask for documentation during an audit.

Option 2: Submit a Reimbursement Claim

If you paid out-of-pocket, gather the following documents before submitting:

• Itemized pharmacy receipt showing drug name, dispensing date, and amount paid
• Explanation of Benefits (EOB) from your insurer if insurance processed the claim first
• Letter of Medical Necessity (LMN) if your plan administrator requires one for specialty drugs

Submit through your HSA custodian's web portal (Fidelity, HealthEquity, HSA Bank, etc.) or your FSA administrator's app. Processing times range from 3 to 10 business days. Reimbursement arrives as a direct deposit or check.

Documentation Tips to Avoid Denied Claims

A common rejection reason is a receipt that lists only a transaction total without the drug name. Always request an itemized receipt. Some specialty pharmacies send paperless receipts by email; save those immediately. If your FSA administrator flags Praluent as requiring pre-approval, ask your cardiologist or lipidologist to provide a brief LMN citing the ACC/AHA 2022 guideline threshold for PCSK9 inhibitor initiation.

What Praluent Actually Costs Without Assistance

Understanding list price is necessary context before layering savings programs.

The wholesale acquisition cost (WAC) for Praluent is approximately $600 to $700 per pre-filled pen for a one-month supply at the 75 mg every-two-weeks dosing, according to pharmacy benefit data published in 2025. At the 150 mg every-two-weeks dose, costs run similarly. Annual list-price spending can approach $7,000 to $8,500 before any discounts.

That figure matters because a single HSA contribution of $4,300 (self-only 2026 limit) does not cover a full year at list price. Stacking HSA/FSA with other programs is the practical path for most patients.

ODYSSEY OUTCOMES (N=18,924, median follow-up 2.8 years) demonstrated that alirocumab 75 mg or 150 mg every two weeks reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15% compared with placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001). See the full trial results in NEJM. That clinical benefit makes cost optimization worth the administrative effort.

Praluent Manufacturer Savings Programs

The Regeneron/Sanofi Praluent Savings Card

Regeneron and Sanofi operate a patient savings program for commercially insured patients. As of 2026, eligible patients may pay as little as $0 per month, with a maximum benefit cap that varies by plan year. Patients with Medicare, Medicaid, or other federal health insurance are not eligible for manufacturer copay cards under federal anti-kickback rules.

Enrollment is online at the Praluent website or by calling the program phone line. You receive a copay card or digital savings code to present at the pharmacy. The card applies after insurance processes the claim, reducing the patient portion.

Can You Use HSA/FSA Funds on Top of a Copay Card?

This is a frequent question and the answer requires precision. IRS rules prohibit double-dipping: you cannot use tax-advantaged dollars to pay an amount that was already covered by another benefit. If the copay card reduces your out-of-pocket to $0, there is nothing left to submit to your HSA or FSA. If the copay card covers part of your cost but you still owe a residual balance, that residual balance is HSA/FSA eligible. Always document exactly what you paid net of the copay card.

Praluent Patient Assistance Program (PAP) for Uninsured Patients

Patients without insurance who meet income criteria may qualify for Regeneron's RxAssist-listed patient assistance program, which can provide Praluent at no cost. Income thresholds typically fall at or below 400% of the Federal Poverty Level, though program terms change. Applications require proof of income, a prescriber signature, and documentation of insurance status.

For uninsured patients using an HSA is not an option (HSA enrollment requires an HDHP), but the PAP route bypasses that constraint entirely. The FDA's guidance on patient assistance programs outlines how to evaluate program legitimacy.

How PCSK9 Inhibitors Work and Why Cost Matters

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally tags LDL receptors on hepatocytes for degradation; blocking it keeps more receptors available, clearing more LDL-C from circulation.

In ODYSSEY LONG TERM (N=2,341, 78 weeks), alirocumab 150 mg every two weeks reduced LDL-C by 61.9% from baseline versus 0.8% for placebo (P<0.001). That data is published in NEJM. These reductions are clinically relevant for patients with HeFH or established ASCVD who cannot reach guideline-recommended LDL-C targets on statins alone.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, if the LDL-C level remains ≥70 mg/dL (or non-HDL-C ≥100 mg/dL) on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable (Class IIa, Level of Evidence: A)." Read the full guideline at the AHA Journals. When a drug carries that evidence weight, ensuring consistent access through HSA/FSA optimization is not a minor administrative task; it directly supports medication adherence.

Why Adherence to PCSK9 Inhibitors Is Fragile

Discontinuation rates for PCSK9 inhibitors are high when cost barriers are unresolved. A 2020 analysis in JAMA Cardiology (N=5,765) found that 40% of patients who initiated a PCSK9 inhibitor had discontinued within 12 months, with cost-related barriers cited most frequently. See that analysis at JAMA Network. Proactively setting up HSA/FSA auto-pay before the first fill reduces the decision friction that leads to missed doses.

Step-by-Step: Setting Up Ongoing HSA Auto-Pay for Praluent

Consistent payment setup reduces the chance of a gap in therapy caused by billing confusion.

1. Confirm your pharmacy accepts HSA debit cards for specialty medications. Most do, but some specialty mail-order pharmacies require a brief enrollment step.
2. Register your HSA debit card with the specialty pharmacy's auto-refill system. The card is charged automatically at each fill cycle.
3. Set a calendar alert 30 days before your FSA plan year ends to review remaining FSA balance. If balance remains, schedule your next Praluent fill to draw it down.
4. Keep a digital folder with itemized receipts for the tax year. If you are audited, you need documentation that each charge was for a qualified medical expense.
5. When your insurance EOB arrives (usually 2 to 4 weeks after fill), verify that the insurer processed the claim correctly before submitting any HSA reimbursement request. Submitting before the EOB generates inconsistent records.

Prior Authorization and Its Interaction With HSA/FSA Timing

Most commercial insurers require prior authorization (PA) before covering Praluent. The PA process typically requires documentation of an LDL-C level above threshold, a history of maximally tolerated statin therapy, and a diagnosis of HeFH or ASCVD.

PA approval delays are common and can interrupt your first fill by weeks. During that gap, some patients pay cash using HSA/FSA funds at a discount pharmacy to avoid missing a dose. GoodRx coupons are not HSA/FSA eligible on their own, but if you pay cash using your HSA card and the pharmacy accepts it, the transaction is valid as long as the drug is prescribed. The distinction: the eligibility comes from the prescription status of the drug, not from the payment method used to get the discount price.

The HealthRX PA-to-HSA Bridge Framework: When a patient's PA is pending, the prescribing clinician should provide a written prescription with explicit dosing so the patient can fill one cycle at cash price using HSA funds. Once PA approves, the insurance copay structure takes over, and any remaining patient cost is again HSA/FSA eligible. This two-phase approach prevents a therapy gap of 2 to 6 weeks while administrative processes resolve.

Special Situations: Medicare, Medicaid, and HSA Ineligibility

Patients enrolled in Medicare Part D cannot legally use a manufacturer copay card for Praluent, but HSA/FSA eligibility still applies if they have remaining account balances. However, Medicare enrollees cannot contribute new money to an HSA (IRS rules prohibit HSA contributions once Medicare Part A or B begins). Spending down an existing HSA balance on Praluent remains permissible.

Medicaid patients who receive Praluent at low or no cost through the state program have no out-of-pocket cost to submit. HSA/FSA reimbursement is only valid for amounts the patient actually paid.

Patients on a general-purpose FSA who transition mid-year to Medicare may have a short window to spend remaining FSA funds before losing them. Praluent is a legitimate qualifying expense to clear that balance.

Comparing Alirocumab to Evolocumab for HSA/FSA Purposes

Evolocumab (Repatha) is the other FDA-approved PCSK9 inhibitor monoclonal antibody. Both are equally HSA/FSA eligible by the same IRS prescription-drug rule. The choice between them is clinical, driven by trial data, prescriber preference, and formulary placement at your specific insurer.

FOURIER (N=27,564), the landmark evolocumab outcomes trial, showed a 15% reduction in the primary composite endpoint versus placebo (P<0.001). See the FOURIER trial in NEJM. ODYSSEY OUTCOMES showed a similar 15% reduction for alirocumab. Neither drug has a head-to-head outcomes trial. Formulary tier placement often determines which drug costs less after insurance, making it worth checking both savings programs before committing to one.

Frequently Asked Questions